ScholarIQanswers from OpenAlex & ORCID
Wilson H. Miller
ResearcherPublications, citations & collaboration network
Wilson H. Miller is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wilson H. Miller have?
ScholarIQindexed works
Wilson H. Miller has 624 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wilson H. Miller have?
ScholarIQcitation count
Wilson H. Miller has 46,507 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wilson H. Miller?
ScholarIQh-index
Wilson H. Miller has an h-index of 81 in OpenAlex.
What is the i10-index of Wilson H. Miller?
ScholarIQi10-index
Wilson H. Miller has an i10-index of 250 in OpenAlex.
What is the ORCID of Wilson H. Miller?
ScholarIQorcid
The ORCID for Wilson H. Miller is on the source record.
What is the OpenAlex record for Wilson H. Miller?
ScholarIQopenalex
The OpenAlex for Wilson H. Miller is on the source record.
What are the most-cited papers on Wilson H. Miller?
ScholarIQmost cited works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, Brian I. Rini, Laurence Albigès, Matthew T. Campbell, Balaji Venugopal, Christian Kollmannsberger, Sylvie Négrier, Motohide Uemura, Jae L. Lee, Aleksandr Vasiliev, Wilson H. Miller, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Jens Bedke, B. Yа. Alekseev, Jing Wang, Mariangela Mariani, Paul B. Robbins, Aleksander Chudnovsky, Camilla Fowst, Subramanian Hariharan, Bo Huang, Alessandra di Pietro, Toni K. Choueiri
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodón, Jean‐Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia M. Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña, Yohann Loriot, Mohammad Afshar, Vincent A. Miller, Fanny Wunder, Catherine Bresson, Jean-François Martini, Jacques Raynaud, John Mendelsohn, Gerald Batist, Amir Onn, Josep Tabernero, Richard L. Schilsky, Vladimir Lazar, J. Jack Lee, Razelle Kurzrock
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Aurélien Marabelle, Aaron R. Hansen, A. De Jesus Acosta, Wilson H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin, Lei Xu, Fan Jin, Kevin Norwood, Michele Maio